Gene and Cell Therapy Educational Series Part 6: Genetically-engineered Cell-based Therapy: Product Pathway Logistics and Considerations

ACPE Activity Number: 0204-0000-25-183-H05-P
Release Date: September 15, 2025
Expiration Date: September 15, 2027
Activity Type: Knowledge-based
CE Credits: 0.5 contact hour
Activity Fee: Member – Free / Non-Member – Not Available

Activity Overview

Gene and cell therapies are quickly integrating into pharmacy practice and present unique challenges not encountered with traditional medications in the clinical pharmacy setting. Health-system pharmacies must take an active role in onboarding these therapies including evaluating biosafety precautions along the medication use pathway, assisting with the development of infrastructure to administer and monitor these therapies, and identifying the practical and financial implications of these therapies within the health-system.  

With the increased use of cell therapy for treatment of various diagnoses, pharmacists may need an introduction or additional background regarding the development of cell therapy products. Additional details and discussion about collection, processing to final dose product, dose storage/preparation/administration, and safe handling may provide more insight and considerations applicable for pharmacy practice. This activity will discuss clinical and safety strategies for implementation that will translate to better care for patients and a safer handling environment for providers, patients, and caregivers.

Accreditation

Target Audience

This activity was planned to provide initial or additional insight to practitioners that might be unfamiliar with the details regarding the dose delivery pathway of cell therapy, including collection, identification, storage, preparation, administration, and disposal. Additional audience members may include those practitioners that are seeing an increase in cellular therapy dose provision to their patient population.

Learning Objectives

After participating in this CPE activity, participants should be able to:

Describe cell-based therapy dose preparation from sources of collection, processing, and final dose presentation.
Identify specific requirements and recommendations regarding product storage, handling, and disposal.
Discuss practical steps that can be used to provide a safe and complete dosing pathway for patients receiving cell-based therapy.

Schedule of Activities

Faculty

Relevant Financial Relationship Disclosure

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Methods and CE Requirements

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.

Online Program

Member

Free

Non-Member

N/A